Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
NOX
vs
S
S&P/ASX 300
NOX
Over the past 12 months, NOX has underperformed S&P/ASX 300, delivering a return of -42% compared to S&P/ASX 300's 2% drop.
Stocks Performance
NOX vs S&P/ASX 300
Performance Gap
NOX vs S&P/ASX 300
Performance By Year
NOX vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Noxopharm Ltd
Glance View
Noxopharm Ltd is an Australian drug-development company that works on new medicines for cancer and immune-related diseases. It does not run a pharmacy or sell finished medicines to consumers. Instead, it discovers drug candidates, tests them in preclinical and clinical studies, and tries to move the most promising ones toward licensing or partnership deals. The company’s main customers are not patients today but larger pharmaceutical partners, researchers, and clinical trial sites. Its business depends on creating intellectual property and advancing programs far enough that another drug company may pay to license, co-develop, or commercialize them. That means Noxopharm makes money mainly from research funding, collaboration income, and potential deal payments tied to its drug pipeline. What makes Noxopharm different is its role as an early-stage biotech focused on new chemical and biological approaches rather than on manufacturing or distributing medicines at scale. Its value comes from the science behind its drug candidates and from acting as a pipeline builder that can hand successful programs to larger companies with the resources to develop and market them.
